Company Contents
Quick Facts & Snapshot
Summary
The arteriotomy closure devices market is transitioning from early adoption to scaled, protocol-driven use across catheterization labs worldwide. Demand is propelled by efficiency, faster ambulation, and safety versus manual compression, while hospitals consolidate vendors around proven brands. Leading Arteriotomy Closure Devices market companies are competing in a segment projected to grow at 6.80% CAGR through 2032, from US$ 1.33 Billion in 2025 to US$ 2.12 Billion.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
The rankings of Arteriotomy Closure Devices market companies are based on a composite, multi-criteria scoring framework. Core inputs include estimated 2025 arteriotomy closure device revenue, multi-year growth trajectory, and share of global procedures supported. We also factor in project wins with high-volume cath labs, breadth of installed base, and geographic diversification. Technology differentiation covers portfolio depth across suture, clip, and collagen-based systems, plus evidence from clinical trials and registry data. Service capability is assessed through training reach, field support density, and the ability to sustain long-term maintenance, user education, and post-market surveillance. Strategic factors include M&A, partnerships with imaging or catheter vendors, and investment in R&D. Each company receives weighted scores across these criteria, which are normalized and combined to generate final rankings.
Top 10 Companies in Arteriotomy Closure Devices
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Terumo Corporation
Terumo Corporation is a diversified cardiovascular and endovascular leader with a deep portfolio of femoral and radial access and closure solutions.
Abbott Laboratories
Abbott Laboratories is a global cardiovascular powerhouse offering suture-mediated and clip-based arteriotomy closure devices integrated with its interventional portfolio.
Cardinal Health, Inc. (Cordis)
Cordis, under Cardinal Health, delivers widely adopted vascular closure devices that emphasize simplicity, patient comfort, and consistent hemostasis outcomes.
Boston Scientific Corporation
Boston Scientific integrates arteriotomy closure into a broader cardiovascular ecosystem spanning PCI, structural heart, and peripheral interventions.
Teleflex Incorporated
Teleflex provides differentiated large-bore vascular closure solutions that address complex structural heart and endovascular repair procedures.
BD (Becton, Dickinson and Company)
BD leverages its vascular access franchise to offer integrated access and closure solutions for interventional cardiology and radiology.
Medtronic plc
Medtronic integrates closure solutions within comprehensive structural heart and endovascular therapy platforms for complex procedures.
Merit Medical Systems, Inc.
Merit Medical serves interventional cardiology and radiology with access, hemostasis, and emerging arteriotomy closure solutions.
Vasorum Ltd.
Vasorum is a specialized vascular closure innovator focused on compact, metallic clip-based arteriotomy closure technologies.
Essential Medical, Inc. (part of Teleflex territory partnerships)
Essential Medical develops novel large-bore closure technologies that complement structural heart and complex endovascular interventions.
SWOT Leaders
Terumo Corporation
SWOT Snapshot
Broad, clinically validated closure portfolio, strong brand equity, and deep relationships with interventional cardiologists globally.
Premium pricing can limit penetration in cost-sensitive markets and among smaller standalone cath labs.
Rising PCI and peripheral interventions in Asia Pacific and Latin America, plus hospital standardization on single-vendor closure protocols.
Intensifying competition from Abbott and Teleflex in large-bore closure and potential pricing pressure from regional manufacturers.
Abbott Laboratories
SWOT Snapshot
Market-leading large-bore suture-mediated systems and robust clinical evidence base for complex structural heart procedures.
High dependence on procedure volumes in mature markets and exposure to reimbursement changes in the U.S. and Europe.
Expansion of TAVR, EVAR, and complex PCI in emerging markets, plus digital integration of access and closure planning tools.
Possible disruption from novel collagen or clip technologies and increasing hospital pushback on premium pricing structures.
Cardinal Health, Inc. (Cordis)
SWOT Snapshot
User-friendly closure devices with attractive value positioning and broad distributor network in secondary and tertiary markets.
Smaller innovation budget and fewer flagship clinical trials than top-tier competitors limit perception as technology leader.
Growth in day-case PCI programs and emerging-market cath lab expansion seeking cost-effective, easy-to-use closure solutions.
Aggressive portfolio moves by integrated giants bundling closure with cath lab consumables and access kits at discounted rates.
Arteriotomy Closure Devices Market Regional Competitive Landscape
North America remains the largest regional market, driven by high PCI, TAVR, and EVAR volumes, early adoption of outpatient cath labs, and strong reimbursement. Terumo Corporation, Abbott Laboratories, and Teleflex dominate, while Cardianl Health’s Cordis and BD leverage broad distribution. Arteriotomy Closure Devices market companies compete heavily on evidence, workflow efficiency, and same-day discharge enablement.
Europe shows balanced adoption across collagen plug, suture-mediated, and clip-based systems, with strong emphasis on clinical evidence and cost-effectiveness. Terumo, Abbott, Boston Scientific, and Vasorum are highly visible, and procurement is increasingly centralized. Arteriotomy Closure Devices market companies must navigate heterogeneous reimbursement while proving value in shortened length-of-stay and reduced nursing time.
Asia Pacific is the fastest-growing region, with expanding cath lab infrastructure in China, India, and Southeast Asia. Terumo benefits from historical presence and localized manufacturing, while Abbott and BD ramp distribution and training. Price sensitivity is high, favoring scalable, reliable devices. Arteriotomy Closure Devices market companies increasingly customize training and service models to local operator experience levels.
Latin America and the Middle East show rising adoption as PCI and structural heart programs scale in private hospital networks. Cardinal Health’s Cordis, Terumo, and Abbott pursue distributor-led models, while Teleflex targets high-complexity centers for large-bore closure. Arteriotomy Closure Devices market companies that provide flexible financing, education, and inventory management gain competitive advantage.
In emerging Eastern Europe and Africa, market penetration is still modest, with manual compression widely used due to budget constraints. Nonetheless, reference centers adopt devices from Terumo, Abbott, and smaller players like Vasorum for complex and high-risk cases. Arteriotomy Closure Devices market companies emphasize training, simplified devices, and pragmatic economics to accelerate substitution away from manual techniques.
Arteriotomy Closure Devices Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Developing AI-guided closure systems that automatically adjust deployment parameters based on ultrasound feedback for consistent hemostasis and reduced operator variability.
Engineering fully bioresorbable composite plugs designed for rapid seal formation with minimal foreign-body response and simplified single-step deployment.
Combining smart access sheaths with integrated closure mechanisms, enabling single-device access and arteriotomy sealing for high-throughput cath labs.
Offering cost-optimized closure devices tailored for emerging markets, with simplified ergonomics and compatibility with widely used femoral introducer sheaths.
Developing sensor-enabled closure plugs that confirm intravascular versus extravascular positioning in real time, enhancing safety in complex anatomies.
Arteriotomy Closure Devices Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Arteriotomy Closure Devices market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Arteriotomy Closure Devicesmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.